BVF PARTNERS L P/IL Insider Trading Transactions
Get free email notifications about insider trading for BVF PARTNERS L P/IL.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of BVF PARTNERS L P/IL. BVF PARTNERS L P/IL is in KENT INTERNATIONAL HOLDINGS INC ($CRTQ) and 10% Owner in LIGAND PHARMACEUTICALS INC ($LGND) and 10% Owner in Capstone Therapeutics Corp. ($CAPS) and 10% Owner in REPLIGEN CORP ($RGEN) and 10% Owner in AVIGEN INC \DE ($AVGN) and 10% Owner in NEUROCRINE BIOSCIENCES INC ($NBIX) and 10% Owner in Astex Pharmaceuticals, Inc ($SUPG) and 10% Owner in ARQULE INC ($ARQL) and 10% Owner in NEUROBIOLOGICAL TECHNOLOGIES INC /CA/ ($NTII) and 10% Owner in RIGEL PHARMACEUTICALS INC ($RIGL) and 10% Owner in ARRAY BIOPHARMA INC ($ARRY) and 10% Owner in DYNAVAX TECHNOLOGIES CORP ($DVAX) and 10% Owner in EPIRUS Biopharmaceuticals, Inc. ($CRXX) and 10% Owner in CATALYST BIOSCIENCES, INC. ($CBIO) and 10% Owner in ICAGEN INC ($ICGN) and 10% Owner in ChemoCentryx, Inc. ($CCXI) and 10% Owner in Celera CORP ($CRA) and 10% Owner in ABBOTT BIOTHERAPEUTICS CORP ($FACT).
Latest Insider Trading Transactions of BVF PARTNERS L P/IL
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, FACT, ARQL, ARRY, SUPG, AVGN, CAPS, CBIO, CRA, CCXI, DVAX, CRXX, ICGN, CRTQ, LGND, NTII, NBIX, RGEN, RIGL
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jul 03 2014 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Sell | J | 0.30 | 616,563 | 184,969 | 3,993,637 | 4.6 M to 4 M (-13.37 %) |
Nov 20 2013 | RIGL | RIGEL PHARMACEUTIC ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.64 | 153,056 | 404,343 | 646,559 | 799.6 K to 646.6 K (-19.14 %) |
Nov 20 2013 | RIGL | RIGEL PHARMACEUTIC ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 2.64 | 331,566 | 875,931 | 1,123,848 | 1.5 M to 1.1 M (-22.78 %) |
Nov 29 2013 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 57.07 | 154,578 | 8,822,493 | 2,008,834 | 2.2 M to 2 M (-7.15 %) |
Nov 29 2013 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 57.07 | 27,058 | 1,544,327 | 101,523 | 128.6 K to 101.5 K (-21.04 %) |
Nov 29 2013 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 57.07 | 50,934 | 2,907,043 | 190,967 | 241.9 K to 191 K (-21.06 %) |
Nov 29 2013 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 57.07 | 86,435 | 4,933,252 | 324,836 | 411.3 K to 324.8 K (-21.02 %) |
Nov 29 2013 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 57.57 | 34,917 | 2,010,172 | 128,581 | 163.5 K to 128.6 K (-21.36 %) |
Nov 29 2013 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 57.57 | 54,444 | 3,134,341 | 241,901 | 296.3 K to 241.9 K (-18.37 %) |
Nov 29 2013 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 57.57 | 119,139 | 6,858,832 | 411,271 | 530.4 K to 411.3 K (-22.46 %) |
Dec 05 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.03 | 41,451 | 208,358 | 1,251,914 | 1.2 M to 1.3 M (+3.42 %) |
Dec 05 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.03 | 82,849 | 416,449 | 2,162,381 | 2.1 M to 2.2 M (+3.98 %) |
Dec 05 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.98 | 16,175 | 80,590 | 1,210,463 | 1.2 M to 1.2 M (+1.35 %) |
Dec 05 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.98 | 49,325 | 245,757 | 2,079,532 | 2 M to 2.1 M (+2.43 %) |
Nov 06 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.69 | 8,371 | 39,235 | 1,194,288 | 1.2 M to 1.2 M (+0.71 %) |
Nov 06 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.69 | 11,985 | 56,174 | 2,030,207 | 2 M to 2 M (+0.59 %) |
Nov 06 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.97 | 74,684 | 370,978 | 1,185,917 | 1.1 M to 1.2 M (+6.72 %) |
Nov 06 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.97 | 35,526 | 176,468 | 2,018,222 | 2 M to 2 M (+1.79 %) |
Nov 06 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.90 | 5,500 | 26,944 | 1,111,233 | 1.1 M to 1.1 M (+0.50 %) |
Nov 01 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.92 | 25,154 | 123,775 | 1,105,733 | 1.1 M to 1.1 M (+2.33 %) |
Nov 01 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.92 | 45,406 | 223,429 | 1,982,696 | 1.9 M to 2 M (+2.34 %) |
Nov 01 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.97 | 44,584 | 221,373 | 1,080,579 | 1 M to 1.1 M (+4.30 %) |
Nov 01 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.97 | 79,998 | 397,214 | 1,937,290 | 1.9 M to 1.9 M (+4.31 %) |
Nov 01 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.04 | 50,339 | 253,693 | 1,035,995 | 985.7 K to 1 M (+5.11 %) |
Nov 01 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.04 | 90,744 | 457,323 | 1,857,292 | 1.8 M to 1.9 M (+5.14 %) |
Oct 10 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.26 | 29,564 | 155,445 | 985,656 | 956.1 K to 985.7 K (+3.09 %) |
Oct 10 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.26 | 53,271 | 280,094 | 1,766,548 | 1.7 M to 1.8 M (+3.11 %) |
Oct 10 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.35 | 401,675 | 2,148,961 | 956,092 | 554.4 K to 956.1 K (+72.45 %) |
Oct 10 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.31 | 30,406 | 161,310 | 554,417 | 524 K to 554.4 K (+5.80 %) |
Oct 10 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.35 | 726,626 | 3,887,449 | 1,713,277 | 986.7 K to 1.7 M (+73.65 %) |
Oct 10 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.31 | 47,812 | 253,652 | 986,651 | 938.8 K to 986.7 K (+5.09 %) |
Oct 07 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.49 | 38,599 | 212,071 | 524,011 | 485.4 K to 524 K (+7.95 %) |
Oct 07 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.49 | 70,826 | 389,132 | 938,839 | 868 K to 938.8 K (+8.16 %) |
Sep 25 2013 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 44.50 | 147,806 | 6,577,367 | 296,345 | 444.2 K to 296.3 K (-33.28 %) |
Sep 25 2013 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Sell | S | 44.50 | 211,217 | 9,399,157 | 530,410 | 741.6 K to 530.4 K (-28.48 %) |
Sep 13 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 6.09 | 3,370 | 20,520 | 485,412 | 482 K to 485.4 K (+0.70 %) |
Sep 13 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 6.09 | 6,307 | 38,404 | 868,013 | 861.7 K to 868 K (+0.73 %) |
Sep 13 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.94 | 105,892 | 629,136 | 482,042 | 376.2 K to 482 K (+28.15 %) |
Sep 13 2013 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.94 | 210,066 | 1,248,065 | 861,706 | 651.6 K to 861.7 K (+32.24 %) |
Jan 25 2013 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 19.78 | 39,600 | 783,181 | 2,163,412 | 2.1 M to 2.2 M (+1.86 %) |
Nov 19 2012 | CBIO | CATALYST BIOSCIENC ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.11 | 26,800 | 136,902 | 1,523,707 | 1.5 M to 1.5 M (+1.79 %) |
Nov 19 2012 | CBIO | CATALYST BIOSCIENC ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.11 | 46,700 | 238,558 | 2,646,619 | 2.6 M to 2.6 M (+1.80 %) |
Nov 19 2012 | CBIO | CATALYST BIOSCIENC ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.00 | 444,649 | 1,778,596 | 1,496,907 | 1.1 M to 1.5 M (+42.26 %) |
Nov 19 2012 | CBIO | CATALYST BIOSCIENC ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.00 | 772,063 | 3,088,252 | 2,599,919 | 1.8 M to 2.6 M (+42.24 %) |
Nov 09 2012 | CBIO | CATALYST BIOSCIENC ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.01 | 17,400 | 69,718 | 1,052,258 | 1 M to 1.1 M (+1.68 %) |
Nov 09 2012 | CBIO | CATALYST BIOSCIENC ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.01 | 31,929 | 127,933 | 1,827,856 | 1.8 M to 1.8 M (+1.78 %) |
Nov 09 2012 | CBIO | CATALYST BIOSCIENC ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.08 | 8,800 | 35,915 | 1,034,858 | 1 M to 1 M (+0.86 %) |
Nov 09 2012 | CBIO | CATALYST BIOSCIENC ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.08 | 14,300 | 58,361 | 1,795,927 | 1.8 M to 1.8 M (+0.80 %) |
Nov 02 2012 | CBIO | CATALYST BIOSCIENC ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.05 | 21,500 | 87,150 | 1,026,058 | 1 M to 1 M (+2.14 %) |
Nov 02 2012 | CBIO | CATALYST BIOSCIENC ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.05 | 36,100 | 146,331 | 1,781,627 | 1.7 M to 1.8 M (+2.07 %) |
Nov 02 2012 | CBIO | CATALYST BIOSCIENC ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.05 | 23,400 | 94,688 | 1,004,558 | 981.2 K to 1 M (+2.38 %) |
Nov 02 2012 | CBIO | CATALYST BIOSCIENC ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.05 | 6,700 | 27,112 | 1,745,527 | 1.7 M to 1.7 M (+0.39 %) |
Nov 02 2012 | CBIO | CATALYST BIOSCIENC ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.06 | 5,300 | 21,495 | 981,158 | 975.9 K to 981.2 K (+0.54 %) |
Nov 02 2012 | CBIO | CATALYST BIOSCIENC ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 4.06 | 46,700 | 189,401 | 1,738,827 | 1.7 M to 1.7 M (+2.76 %) |
Dec 18 2012 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 18.63 | 5,386 | 100,365 | 2,123,812 | 2.1 M to 2.1 M (+0.25 %) |
Dec 10 2012 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 17.94 | 50,100 | 898,959 | 2,118,426 | 2.1 M to 2.1 M (+2.42 %) |
Nov 02 2012 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 14.99 | 4,076 | 61,096 | 741,627 | 737.6 K to 741.6 K (+0.55 %) |
Nov 02 2012 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 15.26 | 12,515 | 190,926 | 737,551 | 725 K to 737.6 K (+1.73 %) |
Nov 08 2012 | CCXI | ChemoCentryx, Inc. | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 12.00 | 40,000 | 479,828 | 3,750,277 | 3.7 M to 3.8 M (+1.08 %) |
Oct 14 2011 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.96 | 22,300 | 132,797 | 3,527,700 | 3.5 M to 3.5 M (+0.64 %) |
Oct 14 2011 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.96 | 1,000 | 5,955 | 757,600 | 756.6 K to 757.6 K (+0.13 %) |
Oct 14 2011 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.96 | 6,200 | 36,921 | 1,236,665 | 1.2 M to 1.2 M (+0.50 %) |
Oct 12 2011 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.73 | 3,800 | 21,768 | 3,505,400 | 3.5 M to 3.5 M (+0.11 %) |
Oct 12 2011 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.59 | 44,700 | 249,779 | 3,501,600 | 3.5 M to 3.5 M (+1.29 %) |
Oct 12 2011 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.59 | 9,600 | 53,644 | 756,600 | 747 K to 756.6 K (+1.29 %) |
Oct 12 2011 | NBIX | NEUROCRINE BIOSCIE ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 5.59 | 15,800 | 88,289 | 1,230,465 | 1.2 M to 1.2 M (+1.30 %) |
Nov 22 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 10.59 | 280,100 | 2,966,259 | 2,068,326 | 1.8 M to 2.1 M (+15.66 %) |
Nov 22 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 10.59 | 60,100 | 636,459 | 444,151 | 384.1 K to 444.2 K (+15.65 %) |
Nov 22 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 10.59 | 98,171 | 1,039,631 | 725,036 | 626.9 K to 725 K (+15.66 %) |
Nov 22 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 11.01 | 46,426 | 510,965 | 1,788,226 | 1.7 M to 1.8 M (+2.67 %) |
Nov 22 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 11.01 | 9,951 | 109,521 | 384,051 | 374.1 K to 384.1 K (+2.66 %) |
Nov 22 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 11.01 | 16,292 | 179,310 | 626,865 | 610.6 K to 626.9 K (+2.67 %) |
Oct 28 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.91 | 3,800 | 52,866 | 1,741,800 | 1.7 M to 1.7 M (+0.22 %) |
Oct 28 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.91 | 900 | 12,521 | 374,100 | 373.2 K to 374.1 K (+0.24 %) |
Oct 28 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.91 | 1,320 | 18,364 | 610,573 | 609.3 K to 610.6 K (+0.22 %) |
Oct 25 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.93 | 3,000 | 41,780 | 1,738,000 | 1.7 M to 1.7 M (+0.17 %) |
Oct 25 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.93 | 600 | 8,356 | 373,200 | 372.6 K to 373.2 K (+0.16 %) |
Oct 25 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.93 | 1,000 | 13,927 | 609,253 | 608.3 K to 609.3 K (+0.16 %) |
Oct 20 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.93 | 7,600 | 105,895 | 1,735,000 | 1.7 M to 1.7 M (+0.44 %) |
Oct 20 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.93 | 1,600 | 22,294 | 372,600 | 371 K to 372.6 K (+0.43 %) |
Oct 20 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.93 | 2,700 | 37,620 | 608,253 | 605.6 K to 608.3 K (+0.45 %) |
Oct 20 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.73 | 1,400 | 19,228 | 1,727,400 | 1.7 M to 1.7 M (+0.08 %) |
Oct 20 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.73 | 300 | 4,120 | 371,000 | 370.7 K to 371 K (+0.08 %) |
Oct 20 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.73 | 500 | 6,867 | 605,553 | 605.1 K to 605.6 K (+0.08 %) |
Oct 14 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.55 | 14,238 | 192,953 | 1,726,000 | 1.7 M to 1.7 M (+0.83 %) |
Oct 14 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.55 | 3,020 | 40,927 | 370,700 | 367.7 K to 370.7 K (+0.82 %) |
Oct 14 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.55 | 4,995 | 67,692 | 605,053 | 600.1 K to 605.1 K (+0.83 %) |
Oct 14 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.69 | 36,200 | 495,614 | 1,711,762 | 1.7 M to 1.7 M (+2.16 %) |
Oct 14 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.69 | 5,600 | 76,670 | 367,680 | 362.1 K to 367.7 K (+1.55 %) |
Oct 14 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 13.69 | 11,300 | 154,708 | 600,058 | 588.8 K to 600.1 K (+1.92 %) |
Oct 06 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 12.78 | 4,300 | 54,933 | 362,080 | 357.8 K to 362.1 K (+1.20 %) |
Oct 06 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 12.78 | 4,000 | 51,100 | 1,675,562 | 1.7 M to 1.7 M (+0.24 %) |
Oct 06 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 12.78 | 6,100 | 77,928 | 588,758 | 582.7 K to 588.8 K (+1.05 %) |
Dec 28 2011 | CRTQ | KENT INTERNATIONAL ... | BVF PARTNERS L P/IL | Sell | J | 2.50 | 301,154 | 752,885 | 0 | 301.2 K to 0 (-100.00 %) | |
Dec 28 2011 | CRTQ | KENT INTERNATIONAL ... | BVF PARTNERS L P/IL | Sell | J | 2.50 | 129,100 | 322,750 | 0 | 129.1 K to 0 (-100.00 %) | |
Dec 28 2011 | CRTQ | KENT INTERNATIONAL ... | BVF PARTNERS L P/IL | Sell | J | 2.50 | 295,352 | 738,380 | 0 | 295.4 K to 0 (-100.00 %) | |
Dec 05 2011 | ARRY | ARRAY BIOPHARMA IN ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.14 | 2,700 | 5,775 | 4,893,000 | 4.9 M to 4.9 M (+0.06 %) |
Dec 05 2011 | ARRY | ARRAY BIOPHARMA IN ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.14 | 600 | 1,283 | 1,050,900 | 1.1 M to 1.1 M (+0.06 %) |
Dec 05 2011 | ARRY | ARRAY BIOPHARMA IN ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.14 | 1,000 | 2,139 | 1,715,269 | 1.7 M to 1.7 M (+0.06 %) |
Dec 05 2011 | ARRY | ARRAY BIOPHARMA IN ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.10 | 20,500 | 43,034 | 4,890,300 | 4.9 M to 4.9 M (+0.42 %) |
Dec 05 2011 | ARRY | ARRAY BIOPHARMA IN ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.10 | 4,400 | 9,236 | 1,050,300 | 1 M to 1.1 M (+0.42 %) |
Dec 05 2011 | ARRY | ARRAY BIOPHARMA IN ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.10 | 7,200 | 15,114 | 1,714,269 | 1.7 M to 1.7 M (+0.42 %) |
Dec 05 2011 | ARRY | ARRAY BIOPHARMA IN ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.04 | 56,400 | 115,163 | 4,869,800 | 4.8 M to 4.9 M (+1.17 %) |
Dec 05 2011 | ARRY | ARRAY BIOPHARMA IN ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.04 | 9,200 | 18,785 | 1,045,900 | 1 M to 1 M (+0.89 %) |
Dec 05 2011 | ARRY | ARRAY BIOPHARMA IN ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.04 | 17,600 | 35,937 | 1,707,069 | 1.7 M to 1.7 M (+1.04 %) |
Dec 05 2011 | ARRY | ARRAY BIOPHARMA IN ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.21 | 38,000 | 84,029 | 4,813,400 | 4.8 M to 4.8 M (+0.80 %) |
Dec 05 2011 | ARRY | ARRAY BIOPHARMA IN ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.21 | 11,000 | 24,324 | 1,036,700 | 1 M to 1 M (+1.07 %) |
Dec 05 2011 | ARRY | ARRAY BIOPHARMA IN ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 2.21 | 15,253 | 33,729 | 1,689,469 | 1.7 M to 1.7 M (+0.91 %) |
Aug 22 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 11.93 | 19,000 | 226,590 | 1,671,562 | 1.7 M to 1.7 M (+1.15 %) |
Aug 22 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 11.93 | 400 | 4,770 | 357,780 | 357.4 K to 357.8 K (+0.11 %) |
Aug 22 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 11.93 | 1,900 | 22,659 | 582,658 | 580.8 K to 582.7 K (+0.33 %) |
Aug 22 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 11.91 | 15,700 | 186,996 | 1,652,562 | 1.6 M to 1.7 M (+0.96 %) |
Aug 22 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 11.91 | 871 | 10,374 | 580,758 | 579.9 K to 580.8 K (+0.15 %) |
Aug 15 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 11.19 | 926 | 10,363 | 1,636,862 | 1.6 M to 1.6 M (+0.06 %) |
Aug 15 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 11.19 | 217 | 2,429 | 357,380 | 357.2 K to 357.4 K (+0.06 %) |
Aug 15 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 11.19 | 251 | 2,809 | 579,887 | 579.6 K to 579.9 K (+0.04 %) |
Aug 10 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 10.91 | 148,200 | 1,617,262 | 1,635,936 | 1.5 M to 1.6 M (+9.96 %) |
Aug 10 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 10.91 | 32,400 | 353,571 | 357,163 | 324.8 K to 357.2 K (+9.98 %) |
Aug 10 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 10.91 | 52,400 | 571,825 | 579,636 | 527.2 K to 579.6 K (+9.94 %) |
Aug 10 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 10.86 | 133,000 | 1,444,912 | 1,487,736 | 1.4 M to 1.5 M (+9.82 %) |
Aug 10 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 10.86 | 13,200 | 143,405 | 324,763 | 311.6 K to 324.8 K (+4.24 %) |
Aug 10 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 10.86 | 44,700 | 485,621 | 527,236 | 482.5 K to 527.2 K (+9.26 %) |
Aug 10 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 11.20 | 156,100 | 1,748,944 | 1,354,736 | 1.2 M to 1.4 M (+13.02 %) |
Aug 10 2011 | LGND | LIGAND PHARMACEUTI ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 11.20 | 19,700 | 220,719 | 482,536 | 462.8 K to 482.5 K (+4.26 %) |
Sep 09 2011 | ICGN | ICAGEN INC | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 6.00 | 80,900 | 485,724 | 625,400 | 544.5 K to 625.4 K (+14.86 %) |
Sep 09 2011 | ICGN | ICAGEN INC | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 6.00 | 17,400 | 104,470 | 135,100 | 117.7 K to 135.1 K (+14.78 %) |
Sep 09 2011 | ICGN | ICAGEN INC | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 6.00 | 28,400 | 170,514 | 219,700 | 191.3 K to 219.7 K (+14.85 %) |
Sep 08 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.26 | 199,600 | 51,696 | 4,610,200 | 4.4 M to 4.6 M (+4.53 %) |
Sep 08 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.26 | 43,200 | 11,189 | 996,200 | 953 K to 996.2 K (+4.53 %) |
Sep 08 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.26 | 70,100 | 18,156 | 1,619,888 | 1.5 M to 1.6 M (+4.52 %) |
Aug 22 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.26 | 5,700 | 1,482 | 4,410,600 | 4.4 M to 4.4 M (+0.13 %) |
Aug 22 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.26 | 1,200 | 312 | 953,000 | 951.8 K to 953 K (+0.13 %) |
Aug 22 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.26 | 1,900 | 494 | 1,549,788 | 1.5 M to 1.5 M (+0.12 %) |
Aug 22 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.26 | 27,800 | 7,228 | 4,404,900 | 4.4 M to 4.4 M (+0.64 %) |
Aug 22 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.26 | 3,100 | 806 | 951,800 | 948.7 K to 951.8 K (+0.33 %) |
Aug 22 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.26 | 8,000 | 2,080 | 1,547,888 | 1.5 M to 1.5 M (+0.52 %) |
Aug 22 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.26 | 31,200 | 8,112 | 4,377,100 | 4.3 M to 4.4 M (+0.72 %) |
Jul 18 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 310,000 | 77,221 | 3,522,300 | 3.2 M to 3.5 M (+9.65 %) |
Jul 18 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 28,900 | 7,199 | 1,258,938 | 1.2 M to 1.3 M (+2.35 %) |
Jul 18 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 19,700 | 4,925 | 3,212,300 | 3.2 M to 3.2 M (+0.62 %) |
Aug 01 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 598,500 | 149,625 | 4,345,900 | 3.7 M to 4.3 M (+15.97 %) |
Aug 01 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 120,700 | 30,175 | 948,700 | 828 K to 948.7 K (+14.58 %) |
Aug 01 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 212,000 | 53,000 | 1,539,888 | 1.3 M to 1.5 M (+15.97 %) |
Aug 01 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 17,100 | 4,275 | 3,747,400 | 3.7 M to 3.7 M (+0.46 %) |
Aug 01 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 5,950 | 1,488 | 1,327,888 | 1.3 M to 1.3 M (+0.45 %) |
Jul 28 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 13,900 | 3,475 | 3,730,300 | 3.7 M to 3.7 M (+0.37 %) |
Jul 28 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 4,500 | 1,125 | 1,321,938 | 1.3 M to 1.3 M (+0.34 %) |
Jul 22 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 194,100 | 48,486 | 3,716,400 | 3.5 M to 3.7 M (+5.51 %) |
Jul 22 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 58,500 | 14,613 | 1,317,438 | 1.3 M to 1.3 M (+4.65 %) |
Jul 05 2011 | CAPS | Capstone Therapeut ... | BVF PARTNERS L P/IL | 10% Owner | Buy | P | 0.25 | 2,850 | 711 | 3,183,600 | 3.2 M to 3.2 M (+0.09 %) |